GPC3 and hemifacial myohyperplasia: Our study showing Glypican-3 expression in both UESL and HMH cases demonstrates that this marker cannot be used to differentiate the two from hepatocellular carcinoma and hepatoblastoma which have been shown to express this antigen [34, 35].